AR087348A1 - Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos - Google Patents

Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos

Info

Publication number
AR087348A1
AR087348A1 ARP120102730A ARP120102730A AR087348A1 AR 087348 A1 AR087348 A1 AR 087348A1 AR P120102730 A ARP120102730 A AR P120102730A AR P120102730 A ARP120102730 A AR P120102730A AR 087348 A1 AR087348 A1 AR 087348A1
Authority
AR
Argentina
Prior art keywords
atoms
alkyl
cycloalkyl
optionally substituted
atom
Prior art date
Application number
ARP120102730A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Christoph Martin Dehnhardt
Peter Jones
Steven Wade Kortum
Yogesh Anil Sabnis
Florian Michel Wakenhut
Gavin Alistair Whitlock
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46826868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087348(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR087348A1 publication Critical patent/AR087348A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)

Abstract

Composiciones que contienen tales compuestos; y a los usos de tales compuestos en el tratamiento de varias enfermedades, en particular asma y COPD.Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), o una de sus sales farmacéuticamente aceptables, o un solvato farmacéuticamente aceptable de dicho compuesto o sal farmacéuticamente aceptable, donde: R1 es halo; R2 es alquilo C1-6 opcionalmente sustituido con uno o más átomos de flúor; X es un enlace, -CO-, -SO2- o -CH2-; R3 es Aril1, Het1 o Het2, cada uno de los cuales está opcionalmente sustituido con 1 sustituyente -Y-R4 y/o 1 - 4 sustituyentes cada uno seleccionado de modo independiente de R5; n es 1 ó 2; Aril1 es fenilo o naftilo; Het1 es (i) un heterociclo aromático de 6 miembros que contiene 1 - 3 átomos de N o (ii) un heterociclo aromático de 5 miembros que contiene (a) 1 - 4 átomos de o (b) 1 átomo de O ó S y 0 - 3 átomos de N; Het2 es (i) un heterociclo aromático bicíclico de 10 miembros que contiene 1 - 4 átomos de N o (ii) un heterociclo aromático bicíclico de 9 miembros que contiene (a) 1 - 4 átomos de N o (b) 1 átomo de O ó S y 0 - 3 átomos de N o (iii) un heterociclo aromático bicíclico de 8 miembros que contiene (a) 1 - 4 átomos de N o (b) 1 átomo de O ó S y 1 - 3 átomos de N o (c) 2 O ó S átomos y 0 - 2 átomos de N; Y es un enlace ó -O-; R4 es Aril2 o Het3; R5 es alquilo C1-6, cicloalquilo C3-8, halo, -CN, -OR6, -NR7R8, -SR6, -SOR9, -SO2R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6SO2R9, -SO2NR7R6, -NR6CONR7R8, -NR6COOR9 o -NR6SO2NR7R8; R6 es H, alquilo C1-6 o cicloalquilo C3-8, dicho alquilo C1-6 está opcionalmente sustituido con halo o cicloalquilo C3-8; R7 y R8 son (a) de modo independiente H, alquilo C1-8 o cicloalquilo C3-8, dicho alquilo C1-6 está opcionalmente sustituido con -NR10R11, donde R10 y R11 son alquilo C1-6 o tomados juntos con el átomo de nitrógeno al que están unidos forman un anillo heterocíclico de 4-, 5- ó 6- miembros saturado que contiene 1 - 2 átomos de nitrógeno o 1 átomo de nitrógeno y 1 átomo de oxígeno, dicho anillo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-6 o cicloalquilo C3-8 o, (b) se toman juntos con el átomo de nitrógeno al que están unidos para formar un anillo heterocíclico de 4, 5 ó 6 miembros que contiene 1 - 2 átomos de nitrógeno o 1 átomo de nitrógeno 1 de oxígeno, dicho anillo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-6 o cicloalquilo C3-8; R9 es alquilo C1-6 o cicloalquilo C3-8; Aril2 es fenilo o naftilo, dicho fenilo y naftilo están opcionalmente sustituido con 1 - 5 sustituyentes seleccionados de alquilo C1-6, cicloalquilo C3-8, halo, -CN, -OR6, -NR7R8, -SR6, -SOR9, -SO2R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6SO2R9, -SO2NR7R8, -NR6CONR7R8, -NR6COOR9 y -NR6SO2NR7R8; y Het3 es un heterociclo monocíclico saturado o parcialmente insaturado de 3 a 8 miembros, que contiene 1 ó 2 heteroátomos seleccionados de O y N, dicho heterociclo está opcionalmente sustituido con 1 - 5 sustituyentes seleccionados de alquilo C1-6, cicloalquilo C3-8, halo, oxo, -OR6, -NR7R8, -SR6, -SOR9, -SO2R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6SO2R9, -SO2NR7R8, -NR6CONR7R8, -NR6COOR9 y -NR6SO2NR7R8.
ARP120102730A 2011-07-27 2012-07-26 Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos AR087348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161512144P 2011-07-27 2011-07-27

Publications (1)

Publication Number Publication Date
AR087348A1 true AR087348A1 (es) 2014-03-19

Family

ID=46826868

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102730A AR087348A1 (es) 2011-07-27 2012-07-26 Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos

Country Status (29)

Country Link
US (2) US8575336B2 (es)
EP (1) EP2736907B1 (es)
JP (1) JP5579351B1 (es)
KR (1) KR20140026627A (es)
CN (1) CN103717599B (es)
AP (1) AP2014007372A0 (es)
AR (1) AR087348A1 (es)
AU (1) AU2012288491A1 (es)
BR (1) BR112014001801A2 (es)
CA (1) CA2841882A1 (es)
CL (1) CL2014000122A1 (es)
CO (1) CO6862160A2 (es)
CR (1) CR20140042A (es)
CU (1) CU20140009A7 (es)
DO (1) DOP2014000016A (es)
EA (1) EA201490357A1 (es)
EC (1) ECSP14013222A (es)
GT (1) GT201400016A (es)
IL (1) IL230662A0 (es)
MA (1) MA35285B1 (es)
MD (1) MD20140002A2 (es)
MX (1) MX2014001004A (es)
NI (1) NI201400005A (es)
PE (1) PE20141059A1 (es)
TN (1) TN2014000033A1 (es)
TW (1) TWI462922B (es)
UA (1) UA108442C2 (es)
UY (1) UY34220A (es)
WO (1) WO2013014567A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
AP2016009562A0 (en) * 2014-05-14 2016-11-30 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016139212A1 (en) 2015-03-04 2016-09-09 F. Hoffmann-La Roche Ag Triazolopyridine compounds and methods of use thereof
CN113750094A (zh) 2015-04-22 2021-12-07 里格尔药品股份有限公司 吡唑化合物以及制备和使用该化合物的方法
WO2017079205A1 (en) * 2015-11-03 2017-05-11 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
EP3831830A1 (en) 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
JP6936236B2 (ja) 2016-02-18 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療化合物、組成物及びその方法の使用
JP7034942B2 (ja) 2016-05-05 2022-03-14 エフ．ホフマン－ラ ロシュ アーゲー ピラゾール誘導体、その組成物及び治療的使用
MY199070A (en) * 2016-06-01 2023-10-12 Bayer Pharma AG Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
KR20190045302A (ko) 2016-09-06 2019-05-02 에프. 호프만-라 로슈 아게 8-(아제티딘-1-일)-[1,2,4]트라이아졸로[1,5-a]피리딘일 화합물 및 이의 조성물 및 사용 방법
JP6900491B2 (ja) 2016-12-29 2021-07-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロピリミジン化合物及びその使用方法
JP6974487B2 (ja) 2017-03-09 2021-12-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ４員ヘテロ環式アミドを含むｊａｋ阻害剤
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
AR111495A1 (es) * 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
CA3059790A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
WO2018215389A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
TW201900648A (zh) 2017-05-22 2019-01-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及組成物以及其使用方法
CN111587250A (zh) 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤およびその中間体を調製するためのプロセス
SG11202103042XA (en) * 2018-10-29 2021-04-29 Theravance Biopharma R&D Ip Llc 2-azabicyclo hexane compound as jak inhibitor
CN114075199A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
WO2020173400A1 (zh) 2019-02-25 2020-09-03 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
BR112021025618A2 (pt) 2019-06-18 2022-02-01 Hoffmann La Roche Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
EP3986899A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
EP3986900A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
AR119857A1 (es) 2019-08-30 2022-01-19 Rigel Pharmaceuticals Inc Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak
EP4071145A4 (en) * 2019-12-30 2023-04-19 Liang Lu JAK INHIBITOR COMPOUND AND ITS USE
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021185305A1 (zh) * 2020-03-18 2021-09-23 四川海思科制药有限公司 一种吲唑衍生物及其在医药上的应用
JP2024524214A (ja) * 2021-06-25 2024-07-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのイミダゾロインダゾール化合物
CN117343063A (zh) * 2022-07-04 2024-01-05 河南迈英诺医药科技有限公司 作为trk抑制剂和/或ret抑制剂的化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
BRPI0410315A (pt) 2003-05-13 2006-05-23 Hoffmann La Roche 2-imidazo-benzotiazóis como ligandos de receptor de adenosina
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US7456195B2 (en) 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US8354399B2 (en) * 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
US8642324B2 (en) 2009-02-05 2014-02-04 Low Impact Limited Continuous flow worm farm
KR101127161B1 (ko) * 2009-07-13 2012-03-20 한국화학연구원 테트라히드로이미다조피리딘기가 치환된 퀴놀리논 화합물
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
PT2464232E (pt) * 2009-08-10 2016-02-01 Samumed Llc Inibidores de indazol da via de sinalização wnt e usos terapêuticos dos mesmos
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles

Also Published As

Publication number Publication date
TWI462922B (zh) 2014-12-01
CR20140042A (es) 2014-03-19
US20130029968A1 (en) 2013-01-31
PE20141059A1 (es) 2014-08-30
JP2014522865A (ja) 2014-09-08
EP2736907A1 (en) 2014-06-04
WO2013014567A1 (en) 2013-01-31
CA2841882A1 (en) 2013-01-31
AU2012288491A1 (en) 2014-01-30
CN103717599B (zh) 2015-11-25
DOP2014000016A (es) 2014-07-15
IL230662A0 (en) 2014-03-31
MA35285B1 (fr) 2014-07-03
CN103717599A (zh) 2014-04-09
MX2014001004A (es) 2014-05-13
JP5579351B1 (ja) 2014-08-27
ECSP14013222A (es) 2014-03-31
GT201400016A (es) 2015-02-19
US8895544B2 (en) 2014-11-25
US8575336B2 (en) 2013-11-05
KR20140026627A (ko) 2014-03-05
TN2014000033A1 (fr) 2015-07-01
MD20140002A2 (ro) 2014-06-30
TW201313712A (zh) 2013-04-01
US20140024634A1 (en) 2014-01-23
CO6862160A2 (es) 2014-02-10
CL2014000122A1 (es) 2014-08-18
EA201490357A1 (ru) 2014-05-30
NI201400005A (es) 2014-04-23
AP2014007372A0 (en) 2014-01-31
BR112014001801A2 (pt) 2017-02-14
UY34220A (es) 2013-02-28
EP2736907B1 (en) 2015-10-07
CU20140009A7 (es) 2014-03-26
UA108442C2 (ru) 2015-04-27

Similar Documents

Publication Publication Date Title
AR087348A1 (es) Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos
NI201600170A (es) Pirazolopiridinas y pirazolopirimidinas
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR114233A1 (es) 3-fenil-isoxazol-in-5-carboxamidas de derivados del ácido ciclopentenilcarboxílico con actividad herbicida
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR090548A1 (es) Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR103574A1 (es) Compuestos tricíclicos y usos de lo mismos en medicina
AR086828A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR094300A1 (es) Derivados de quinolonas
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
AR095347A1 (es) Compuestos orgánicos
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
DOP2011000083A (es) Compuestos de amida utiles en terapia
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc

Legal Events

Date Code Title Description
FB Suspension of granting procedure